Delving into the Latest Updates on CSL-NICD Project (Cellestia Biotech) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

ArthritisImmune System DiseasesInflammation

Inactive Indication-

Originator Organization

Cellestia Biotech AGStartup

Active Organization

Cellestia Biotech AGStartup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractRelapsed T cell acute lymphoblastic leukaemia (T‐ALL) has a very poor prognosis. A 24‐year‐old patient with relapsed high‐risk T‐ALL (PTEN gene deletion; NOTCH1 mutation), was treated with the NOTCH inhibitor CB‐103. Within 1 week of starting CB‐103, the bone marrow was free of T‐ALL blast infiltration (MRD+) and successfully underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Sequential samples of ctDNA to monitor the disease after allo‐HSCT showed a decrease of circulating Notch1 and PTEN alterations. This is the first T‐ALL patient treated with CB‐103. The observed clinical response encourages further exploration of CB‐103 in ALL.

100 Deals associated with CSL-NICD Project (Cellestia Biotech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis	Preclinical	CH	Cellestia Biotech AGStartup	-
Immune System Diseases	Preclinical	CH	Cellestia Biotech AGStartup	-
Inflammation	Preclinical	CH	Cellestia Biotech AGStartup	-